Wide-field swept-source OCT angiography of the periarterial capillary-free zone before and after anti-VEGF therapy for branch retinal vein occlusion

Table 2 Changes of clinical parameters at 3, 6 and 12 months after anti-VEGF treatment in BRVO eyes

Parameters	BL	3 m	6 m	12 m	P
					RM one-way ANOVA	Bonferroni post hoc test*
					RM one-way ANOVA	BL vs. 3 m	BL vs. 6 m	BL vs. 12 m
BCVA (ETDRS letters)	53.56 ± 16.09	63.37 ± 16.96	63.98 ± 13.48	65.67 ± 12.89	< 0.01	< 0.01	< 0.01	< 0.01
CRT (μm)	581.70 ± 191.90	283.70 ± 78.02	286.90 ± 85.19	262.50 ± 47.10	< 0.01	< 0.01	< 0.01	< 0.01
First-order artery
PaCFZ area (mm²)	0.54 ± 0.18	0.47 ± 0.16	0.44 ± 0.16	0.41 ± 0.16	< 0.01	< 0.01	< 0.01	< 0.01
Artery area (mm²)	0.49 ± 0.20	0.50 ± 0.20	0.50 ± 0.19	0.49 ± 0.20	0.05	–	–	–
P/A ratio	1.14 ± 0.22	1.01 ± 0.21	0.94 ± 0.20	0.89 ± 0.17	< 0.01	< 0.01	< 0.01	< 0.01
Second-order artery
PaCFZ area (mm²)	0.96 ± 0.48	0.83 ± 0.41	0.76 ± 0.40	0.73 ± 0.38	< 0.01	< 0.01	< 0.01	< 0.01
Artery area (mm²)	0.60 ± 0.38	0.60 ± 0.37	0.60 ± 0.38	0.59 ± 0.37	0.20	–	–	–
P/A ratio	1.83 ± 0.55	1.57 ± 0.53	1.45 ± 0.52	1.41 ± 0.49	< 0.01	< 0.01	< 0.01	< 0.01

VEGF = vascular endothelial growth factor; BRVO = branch retinal vein occlusion; RM = repeated measures; ANOVA = analysis of variance; BL = baseline; BCVA = best-corrected visual acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; CRT = central retinal thickness; paCFZ = periarterial capillary-free zone; P/A = paCFZ area to artery area
*Adjusted P value

ISSN: 2326-0254